financetom
Business
financetom
/
Business
/
Roche to acquire liver drug developer 89bio for up to $3.5 billion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Roche to acquire liver drug developer 89bio for up to $3.5 billion
Sep 17, 2025 10:48 PM

FRANKFURT (Reuters) -Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alcon Posts Q2 Revenue Miss on Softer Market Conditions, Earnings Beat on Lower Tax Rate, Needham Says
Alcon Posts Q2 Revenue Miss on Softer Market Conditions, Earnings Beat on Lower Tax Rate, Needham Says
Aug 20, 2025
03:03 PM EDT, 08/20/2025 (MT Newswires) -- Alcon ( ALC ) missed Q2 revenue consensus due to softer market conditions and reported earnings-per-share beat on lower tax rate, while its contact lens market share was likely up in the quarter, Needham said in a Wednesday note. The eyecare company on late Tuesday posted Q2 revenue of $2.58 billion on core...
Market Chatter: Take-Two Interactive Software Lays off 80 Employees at Cloud Chamber Studio
Market Chatter: Take-Two Interactive Software Lays off 80 Employees at Cloud Chamber Studio
Aug 20, 2025
03:11 PM EDT, 08/20/2025 (MT Newswires) -- Take-Two Interactive Software ( TTWO ) has downsized workforce at its unit Cloud Chamber by a third, or 80 employees, as part of a reorganization, reported Bloomberg on Wednesday, citing people familiar with the matter. The studio, which is developing the next BioShock game, will delay the launch from a previously planned release...
Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says
Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says
Aug 20, 2025
02:59 PM EDT, 08/20/2025 (MT Newswires) -- Veeva Systems ( VEEV ) is likely to post fiscal Q2 results that come in line to better and maintain its H2 outlook, supported by steady business trends at peers and survey indications of expanded budgets for drug commercialization, Truist said in a Wednesday research report. The brokerage noted, however, that with shares...
-- VitalHub Brief: National Bank Resumes Coverage With Outperform, C$16 Target After Co Closes Its Prior Announced Bought Deal Offering and
-- VitalHub Brief: National Bank Resumes Coverage With Outperform, C$16 Target After Co Closes Its Prior Announced Bought Deal Offering and "Strengthening the Balance Sheet"
Aug 20, 2025
03:04 PM EDT, 08/20/2025 (MT Newswires) -- Price: 12.74, Change: -0.03, Percent Change: -0.23 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved